Weight Loss Drugs: Pancreatitis Risk & Symptoms – Mounjaro, Wegovy
Recent alerts from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) have highlighted potential safety concerns surrounding medications used for obesity and diabetes, specifically Mounjaro (tirzepatida) and Wegovy (semaglutida). The MHRA reported cases of death linked to severe inflammation of the pancreas in individuals using these drugs.
Understanding the Risks
The MHRA recommends that individuals taking medications known as GLP-1 analogs – often referred to as “weight loss pens” – be vigilant for symptoms of intense and persistent abdominal pain, typically accompanied by nausea and vomiting. Healthcare professionals are also advised to inquire about the use of these medications in patients presenting with such symptoms.
Pancreatitis and These Medications
Célio Geraldo de Oliveira Gomes, a gastroenterologist with Rede Mater Dei de Saúde and the Instituto Alfa de Gastroenteologia at UFMG (Universidade Federal de Minas Gerais), explains that the risk of developing pancreatitis while using these medications is considered low. He suggests a possible connection lies in “an abnormal stimulation of pancreatic cells, altering the secretion and composition of digestive enzymes.”
Bruno Halpern, vice president of Abeso (Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica) and director of the Department of Obesity at SBEM (Sociedade Brasileira de Endocrinologia e Metabologia), notes that the potential effects on the pancreas have been a consideration throughout the 20 years of clinical trials. He emphasizes that “over these 20 years, dozens of studies have shown that pancreatitis is an extremely rare adverse effect.”
Existing Risk Factors
Halpern also points out that individuals with pre-existing diabetes and obesity already face a higher risk of pancreatitis. Significant weight loss, which these medications can induce, can potentially lead to gallstones, another factor that may contribute to pancreatitis. However, he clarifies that this relationship does not necessarily mean the medications *cause* the condition.
Felipe Rossi, a bariatric surgeon at Hospital e Maternidade Santa Joana, highlights that GLP-1 analogs commonly cause an increase in pancreatic enzyme levels, particularly lipase, which is also used as a marker for potential pancreatitis. However, he stresses that in most cases, this increase does not indicate the presence of pancreatitis.
Rossi explains that a pancreatitis diagnosis is based on clinical symptoms, including intense, acute abdominal pain alongside nausea and vomiting, and a lipase level more than three times the patient’s baseline. A slight change in lipase levels during routine testing for a patient using these medications, without accompanying symptoms, should not be a cause for alarm. Gomes adds that routine lipase monitoring is not recommended unless there is a clinical suspicion of acute pancreatitis.
What the Future May Hold
Currently, medical professionals have found no robust scientific evidence linking the use of these “weight loss pens” to the development of pancreatic cancer. They also report no discernible difference in pancreatic impact between the active ingredients tirzepatida and semaglutida.
To mitigate potential risks to the pancreas, specialists emphasize the importance of clinical monitoring. Rossi states, “Before starting treatment, it is essential to investigate whether the patient has risk factors for pancreatitis, such as a previous history of the disease, gallstones, very high triglyceride levels, or excessive alcohol consumption.”
Eli Lilly do Brasil, the manufacturer of Mounjaro, notes in a statement that the drug’s label warns that inflammation of the pancreas (acute pancreatitis) is an uncommon adverse reaction. The company advises patients to discuss symptoms of pancreatitis with their doctor and to discontinue treatment if pancreatitis is suspected. Novo Nordisk also confirms that all medications in this class carry a warning regarding the risk of pancreatitis, noting that factors like diabetes and obesity are implicated in its development. They advise patients to be informed about the characteristic symptoms and to discontinue treatment if pancreatitis is suspected, particularly those with a prior history of the condition.
Frequently Asked Questions
What are GLP-1 analogs?
GLP-1 analogs are medications commonly known as “weight loss pens” used for treating obesity and diabetes.
What symptoms should prompt a visit to the doctor?
Intense and persistent abdominal pain, generally accompanied by nausea and vomiting, should prompt individuals taking these medications to seek medical attention.
Is routine lipase monitoring recommended?
No, according to Célio Geraldo de Oliveira Gomes, routine lipase monitoring is not recommended unless there is a clinical suspicion of acute pancreatitis.
Given these recent findings, how might your approach to discussing weight management medications with your healthcare provider change?